Neurobiological Technologies(OTC) NTII

Neurobiological Technologies, Inc. is a biotechnology company that has shifted its focus towards liquidation and dissolution, a plan endorsed by stockholders in 2009. Established in 1987, the company was previously dedicated to developing experimental pharmaceutical treatments for various human ailments.

Products and Services

• Formerly focused on experimental pharmaceutical treatments
• Engaged in the liquidation process since 2009
• Limited operational activities with a small workforce

Growth Outlook

• Company's market cap stands at approximately $2,702
• Current ratio indicates strong liquidity at 35.34
• Cash and short-term investments total around $26.49 million

Financial Highlights

• Recent quarterly revenue of $6.03 million
• Net income of $5.41 million reported in the latest quarter
• Gross profit margin remains high at 99.5%

Neurobiological Technologies, Inc. has undergone significant changes since its inception, transitioning from a research-focused entity to a company in liquidation. The recent financial data indicates a strong liquidity position, with a current ratio of 35.34, suggesting that the company can cover its short-term liabilities effectively. The latest quarterly revenue of $6.03 million and a net income of $5.41 million highlight the company's ability to generate profit despite its ongoing liquidation process. The gross profit margin of 99.5% reflects the company's efficiency in managing its costs relative to its revenue. Overall, while the company is not actively pursuing new growth opportunities, its financial metrics present an interesting case for potential investors.